

Professional

Accuracy

Precision

Regd. No.: 1834

(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:08 PM

Sample ID:

Test Description

Value(s)

Reference Range

Unit

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST /



(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:09 PM

Sample ID:

23863

| Test Description | Value(s) | Reference Range | Unit |
|--|---------------|-----------------|----------|
| | | | |
| | LFT, Liver Fu | nction Test | |
| Bilirubin - Total | 0.72 | 0.00 - 1.00 | mg/dL |
| Method : Serum, Jendrassik Grof | | | m a / dI |
| Bilirubin - Direct | 0.16 | 0.00 - 0.20 | mg/dL |
| Method : Serum, Diazotization | | | mg/dL |
| Bilirubin - Indirect | 0.56 | 0.10 - 0.80 | mg/ di |
| Method : Serum, Calculated | | 0.00 | U/L |
| SGOT | 20.67 | 8 - 33 | 0/2 |
| Method: Serum, UV with P5P, IFCC 37 degree | | 2 25 | U/L |
| SGPT | 28.42 | 3 - 35 | |
| Method: Serum, UV with P5P, IFCC 37 degree | 7.75 | < 38 | U/L |
| GGT-Gamma Glutamyl Transpeptidae | 7.75 | < 30 | |
| Method: Serum, G-glutamyl-carboxy-nitoanilide | 04.20 | 42-141 | U/L |
| Alkaline Phosphatase | 84.32 | 72-111 | |
| Method: PNPP-AMP Buffer/Kinetic | 7.12 | 6.60 - 8.70 | g/dL |
| Total Protein | 1.12 | | |
| Method: Serum, Biuret, reagent blank end point | 4.21 | 3.50 - 5.30 | g/dL |
| Albumin | 7.41 | | |
| Method : Serum, Bromocresol green | 2.91 | 2.00-3.50 | g/dL |
| Globulin | 21.71 | | |
| Method : Serum, EIA | 1.45 | 1.2 - 2.2 | |
| A/G Ratio | | | |
| Method: Serum, EIA | | | |

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST /

MICROBIOLOGIST



(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:10 PM

Sample ID:

23863

/hpf

/hpf

/hpf

Test Description Value(s) Reference Range Unit

Urine(R/M) Routine Examination of Urine

| General Examinat | in | m |
|------------------|----|---|

| Colour | PALE YELLOW | Pale Yellow |
|---------------------------|-------------|---------------|
| Transparency (Appearance) | CLEAR | Clear |
| Deposit | Absent | Absent |
| Reaction (pH) | Acidic 5.5 | 4.5 - 7.0 |
| Specific gravity | 1.010 | 1.005 - 1.030 |
| Chemical Examination | | |
| Urine Protein (Albumin) | Absent | Absent |
| | | 4.1 |

| Urine Glucose (Sugar) | Absent | Absent |
|-------------------------|------------|--------|
| Microscopic Examination | | |
| Red blood cells | Absent | 0-4 |
| Pus cells (WBCs) | 1 - 2 /HPF | 0-9 |
| Epithelial cells | 2 - 3 /HPF | 0-4 |
| Crystals | Absent | Absent |
| Cast | Absent | Absent |
| Bacteria | Absent | Absent |

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:11 PM

Sample ID:

| Test Description | Value(s) | Reference Range | Unit |
|--|----------|---|-------|
| | Lipid P | rofile | |
| Cholesterol-Total Method: Spectrophotometry | 167.09 | Desirable level < 200 Borderline High 200-239 High >or = 240 | mg/dL |
| Triglycerides Method: Serum, Enzymatic, endpoint | 158.17 | Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500 | mg/dL |
| HDL Cholesterol | 41.77 | Normal: > 40 Major Risk for Heart: < 40 | mg/dL |
| Method : Serum, Direct measure-PEG LDL Cholesterol Method : Enzymatic selective protection | 93.69 | Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190 | mg/dL |
| VLDL Cholesterol | 31.63 | 6 - 38 | mg/dL |
| Method : Serum, Enzymatic CHOL/HDL Ratio | 4.00 | 3.5 - 5.0 | |
| Method : Serum, Enzymatic LDL/HDL Ratio Method : Serum, Enzymatic | 2.24 | 2.5 - 3.5 | |
| Note: | | | |
| 8-10 hours fasting sample is required. | | | |

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



Regd. No.: 1834

ZENA HEALTHCARE SERVICES

(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:14 PM

Sample ID:

23863

| Test Description | Value(s) | Reference Range | Unit |
|-----------------------------------|-------------|-----------------|------------|
| | | | |
| | Complete Bl | ood Count | |
| Hemoglobin (Hb) | 10.2 | 12.0 - 15.0 | gm/dL |
| Erythrocyte (RBC) Count | 4.14 | 3.8 - 4.8 | mil/cu.mm |
| Packed Cell Volume (PCV) | 33.3 | 36 - 46 | % |
| Mean Cell Volume (MCV) | 80.43 | 83 - 101 | fL |
| Mean Cell Haemoglobin (MCH) | 24.64 | 27 - 32 | pg |
| Mean Corpuscular Hb Concn. (MCHC) | 30.63 | 31.5 - 34.5 | g/dL |
| Red Cell Distribution Width (RDW) | 14.0 | 11.6 - 14.0 | % |
| Total Leucocytes (WBC) Count | 7700 | 4000-10000 | cell/cu.mm |
| Neutrophils | 68 | 40 - 80 | % |
| Lymphocytes | 28 | 20 - 40 | % |
| Monocytes | 02 | 2 - 10 | % |
| Eosinophils | 02 | 1 - 6 | % |
| Basophils | 00 | 1-2 | % |
| Platelet Count | 194 | 150 - 410 | 10^3/ul |
| Mean Platelet Volume (MPV) | 11.2 | 7.2 - 11.7 | fL |
| PCT | 0.22 | 0.2 - 0.5 | % |
| PDW | 17.2 | 9.0 - 17.0 | % |

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:12 PM

Sample ID:

| | | | 23003 |
|--|---------------|--|--------|
| est Description | Value(s) | Reference Range | Unit |
| | | | |
| | Glucose, Fas | sting (FBS) | N. IZZ |
| Glucose fasting | 98.69 | 75 - 115 | mg/dL |
| Method : Fluoride Plasma-F, Hexokinase | | | |
| 9 | dlucose, Post | Prandial (PP) | |
| Blood Glucose-Post Prandial | 105.68 | 70 - 140 | mg/dL |
| Method : Hexokinase | | | |
| | 1C. Glycosyla | ated Hemoglobin | |
| | | | % |
| HbA1c (GLYCOSYLATED HEMOGLOBIN), | 3.43 | | |
| BLOOD | | | |
| Method: (HPLC, NGSP certified) | _ | | mg/dL |
| Estimated Average Glucose: | | | |
| Interpretation | | | |
| As per American Diabetes Association (ADA) | | | |
| Reference Group | HbA1c in % | o a constant of the constant o | |
| Non diabetic adults >=18 years | <5.7 | | (4.) |
| At risk (Prediabetes) | 5.7 - 6.4 | | |
| Diagnosing Diabetes | >= 6.5 | | |
| | Age > 19 ye | ears | |
| | | rapy: < 7.0 | |
| Therapeutic goals for glycemic control | Action sug | gested: > 8.0 | |

Note:

1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.

Goal of therapy: <7.5

Age < 19 years

2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

For Home Collection Please Call at Number:

Therapeutic goals for glycemic control

Zena Healthcare Services

Plot No. 119, Opp. Water tank Lane, Near Police Phandi, Saheed Nagar, Bhubaneswar-07 Ph.: 0674-2549902, 9692276908, 8337964922, E-mail: zenahealthcare@gmail.com Website: www.zenacare.in

Wishing Good Health



(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:12 PM

Sample ID:

| Test Description | Value(s) | Reference Range | Unit |
|-------------------|-----------|-----------------|------|
| I Car Describeron | 0.11.0.17 | | |

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

| HbA1c(%) | Mean Plasma Glucose (mg/dL) |
|----------|-----------------------------|
| 6 | 126 |
| 7 | 154 |
| 8 | 183 |
| 9 | 212 |
| 10 | 240 |
| 11 | 269 |
| 12 | 298 |

ESR, Erythrocyte Sedimentation Rate

ESR - Erythrocyte Sedimentation Rate

14

0 - 20

mm/hr

Method: EDTA Whole Blood, Manual Westergren

Interpretation:

- · It indicates presence and intensity of an inflammatory process. It does not diagnose a specific disease. Changes in the ESR are more significant than the abnormal results of a single test.
- It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis and polymyalgia rheumatica.
- It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.

Blood Group ABO & Rh Typing, Blood

Blood Group (ABO typing)

Method: Manual-Hemagglutination

"O"

RhD Factor (Rh Typing)

Method: Manual hemagglutination

Positive

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:12 PM

Sample ID:

23863

| Test Description | Value(s) | Reference Range | Unit |
|--------------------------------|-----------|-----------------|-------|
| | | | |
| | Creati | inine | |
| Creatinine | 0.72 | 0.60 - 1.30 | mg/dL |
| Method : Serum, Jaffe | | | |
| | Uric acid | l, Serum | |
| Uric Acid | 4.83 | 3.4 - 7.0 | mg/dL |
| Method : Uricase, Colorimetric | | | |
| | BUN, S | Serum | |
| BUN-Blood Urea Nitroge | 12 | 10 - 50 | mg/dL |
| Method: Serum, Urease | | | |

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST

(A Unit of Zena Enterprises)

Dear 2:11.

I know receive not check up my TMT


Dental and eye the beause it is

for away know confine and 10 a hunny

because I best my 4 year child at

home.

Kuno Benene





(A Unit of Zena Enterprises)

NAME:-KUNU BEHERA

AGE:-39YRS
Patient ID:-8

REFERRAL:-MEDI-WHEEL

DATE:-13.04.2024 SEX:-FEMALE

CHEST X-RAY PA VEIW SHOWS.

- Both side lung fields are clear.
- Trachea within normal limit.
- Both costophrenic cardiophrenic angle are clear.
- Cardiac shadow within normal limit.
- Media stinum in position

IMPRESSION:-NORMAL STUDY.

Dr.Bhagaban Pradhan
M.D. (Radio diagnosis)

Consultant Radiologist

MATERNITY CARE HOSPITAL

NAME: KUNU BEHERA

SONOGRAPHER : DR.PARUL PATI

AGE-39Y/F

DATE-13/04/2024

USG OF WHOLE ABDOMEN

LIVER: normal in size, shape and parenchymal echotexture. No. SOL seen. Intrahepatic billiary channels normal in caliber and contains no echogenic structure. Portal and hepatic vascular systems within normal limits. P. V. measures 7.2mm.

Gall bladder- Normal seen

SPLEEN: Normal in size, shape and parenchymal echotexture. Spleen measures 11.0cm.

PANCREAS: Normal in size, shape and parenchymal echotexture. Pancreatic duct not dilated.

KIDNEYS: Both the kidneys normal in size, shape and position. Renal cortical echotexture is within normal limits. Cortico medullary differentiation maintained. No evidence of any calculus or hydronephrosis on both sides. Pelvi-calyceal systems appear normal. No focal lesion seen.

Left kidney measures: 9.8 x 5.5cms.

Right kidney measures: 8.9 x 4.3cms.

URETERS: Both ureters not visualized (normal).

Appendix- not visualized.

uterus: uterus is normal in size shape 64.61 X48.38X44.18MM size, and normal

endometrium seen in cavity.

Ovary- Both ovary polycystic in echopattern

Cervix-cervical canal normal, cervix normal

POD- is free of fluid or sol

Impression:Normal study of abdomen and both ovary polycystic.

Regd. No: 5569 MATERNITY CARE HOSPITAL & IVF CENTER A-142/A-143. Sahid Nagar, Bhubaneswar



Professional

Accuracy

Precision

Regd. No.: 1834

ZENA HEALTHCARE SERVICES

(A Unit of Zena Enterprises)

Patient Name: MRS. KUNU BEHERA

Age / Gender: 39 years / Female

Patient ID: 20869

Referral: MEDI WHEEL

Collection Time: 13/04/2024, 12:19 PM

Reporting Time: 14/04/2024, 03:08 PM

Sample ID:

23863

| Test Description | Value(s) | Reference Range | Unit |
|--|-----------------|---|--------|
| | Thyroid Profile | (T3, T4, TSH) | |
| T3-Total | 1.63 | 0.87 - 2.73 | ng/dL |
| Method: CLIA T4-Total | 8.62 | 6.09 - 12.23 | ug/dL |
| Method : CLIA TSH-Ultrasensitive Method : CLIA | 2.34 | 0.45 - 4.5 First Trimester: 0.1-2.5 Second Trimester: 0.2-3.0 | uIU/mL |
| | | Third trimester: 0.3-3.0 | |

Interpretation

| SH | T3 | T4 | Suggested Interpretation for the Thyroid Function Tests Pattern |
|--------------------------|---------------------------|------------------------|--|
| Raised | Within range | Within range | Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism.Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness" |
| Raised | Decreased | Decreased | Chronic Autoimmune Thyroiditis Post thyroidectomy, Post radioiodine Hypothyroid phase of transient thyroiditis" |
| Raised or within range | Raised | Raised or within range | Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose •Drug interference- Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics. |
| Decreased | Raised or within range | Raised or within range | Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion' |
| Decreased | Decreased | Decreased | Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)" |
| Decreased | Raised | Raised | Primary Hyperthyroidism (Graves' disease).Multinodular goitre, Toxic nodule •Transient thyroiditis:Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain's),Gestational thyrotoxicosis with hyperemesis gravidarum" |
| Decreased Within Rang | Raised | Within range | T3 toxicosis •Non-Thyroidal illness |
| Within range | Decreased | Within range | Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%. |

END OF REPORT

For Home Collection Please Call at Number:

Zena Healthcare Services